The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Open accessAbstract
Background Satralizumab, a humanised monoclonal antibody targeting the interleukin-6 receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) when added to immunosuppressant therapy. This study assessed the safety and efficacy of satralizumab monotherapy in patients with the disorder. Methods In this phase 3, double-blind, placebo-controlled, parallel-group trial, we enrolled adults aged 18-74 years with aquaporin-4 antibody seropositive or seronegative NMOSD at 44 investigational sites in 13 countries. Eligible participants had experienced at least one documented NMOSD attack or relapse in the past 12 months and had a score of 6·5 or less on the Expanded Disability Status Scale. Exclusion criteria included clinical relapse 30 days or fewer before baseline. Participants were randomly assigned (2:1) to receive satralizumab 120 mg or visually matched placebo subcutaneously at weeks 0, 2, 4, and every 4 weeks thereafter. Taking immunosuppressants concomitantly was prohibited. The primary endpoint was time to the first protocol-defined relapse, based on the intention-to-treat population and analysed with stratification for two randomisation factors (previous therapy for prevention of attacks and nature of the most recent attack). Safety was assessed in all participants who received at least one dose of satralizumab or placebo. The double-blind phase was due to last until 44 protocol-defined relapses occurred or 1·5 years after random assignment of the last patient enrolled, whichever occurred first; participants could enter an open-label phase after the occurrence of a protocol-defined relapse or at the end of the double-blind phase. The study is registered with ClinicalTrials.gov, NCT02073279. Findings 95 (57%) of 168 screened participants were randomly assigned to treatment (63 to satralizumab; 32 to placebo) between Aug 5, 2014, and April 2, 2017. Protocol-defined relapses occurred in 19 (30%) patients receiving satralizumab and 16 (50%) receiving placebo (hazard ratio 0·45, 95% CI 0·23-0·89; p=0·018). 473·9 adverse events per 100 patient-years occurred in the satralizumab group, as did 495·2 per 100 patient-years in the placebo group; the incidence of serious adverse events and adverse events leading to withdrawal was similar between groups. Interpretation Satralizumab monotherapy reduced the rate of NMOSD relapse compared with placebo in the overall trial population, with a favourable safety profile. The patient population included a ratio of aquaporin-4 antibody seropositive and seronegative patients that was reflective of clinical practice. Satralizumab has the potential to become a valuable treatment option for patients with NMOSD. Funding Chugai Pharmaceutical (Roche).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In any case, the long-term persistence of (re-)activatable autoantigen-specific ThEx cells in patients in remission may well explain the less-than-perfect treatment efficacy of steroid-sparing agents, 64-67 depletion of CD19/CD20 memory B cells, 68,69 as well as exacerbation of disease by b -IFN. 27,70”
From Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases (2024) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649
Self-citationRevised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,568
Self-citationThe spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,182
Self-citation(2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-79 · Cited by 1,506
Interleukin-6, a Major Cytokine in the Central Nervous System
Erta, M., Quintana, A., & Hidalgo, J. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4679 · Cited by 1,093
Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Pittock, S. J., Berthele, A., Fujihara, K., Kim, H. J., Levy, M., Palace, J. A., Nakashima, I., Terzi, M., Totolyan, N. A., Viswanathan, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900866 · Cited by 887
Physiological Roles of Aquaporin-4 in Brain
Nagelhus, E. A., & Ottersen, O. P. (2013) · Physiological Reviews · doi:10.1152/physrev.00011.2013 · Cited by 766
Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31817-3 · Cited by 756
Self-citationTrial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
Yamamura, T., Kleiter, I., Fujihara, K., Palace, J. A., Greenberg, B. M., Zakrzewska‐Pniewska, B., Patti, F., Tsai, C., Saiz, A., Yamazaki, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901747 · Cited by 663
Self-citationChihara, N., Aranami, T., Sato, W., Miyazaki, Y., Miyake, S., Okamoto, T., Ogawa, M., Toda, T., & Yamamura, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017385108 · Cited by 476
Self-citation
Research works printed but not linked: 1
- Williamson M, McEnany M, Maxion-Bergemann S, Ong R. Epidemiologic temporal trends of neuromyelitis optic spectrum disorder in the United States from 2000 to 2015. 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Prague, Czech Republic; Aug 22–26, 2018.
Cited by
Sorted by citations
Items 301–400 of 513
Reduced tolerogenic factor sCD83 in NMOSD and relapsing MOGAD: a potential new therapeutic pathway
Rechtman, A., Zveik, O., Shweiki, L., Hoichman, G., Friedman‐Korn, T., Brill, L., & Vaknin‐Dembinsky, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1620069 · Cited by 3
Real World Effectiveness and Tolerability of Novel Monoclonal Antibodies and Rituximab for NMOSD
Javed, Z., Du, M., Rensel, M. R., Hua, L. H., Hersh, C. M., Abbatemarco, J., Conway, D. S., Ontaneda, D., Cohen, J. A., & Kunchok, A. C. (2025) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70160 · Cited by 3
Wade, J., Štrancar, N., Fernández‐Quintero, M. L., Siebenhaar, S., Jansen, T., Meier, E. P. W., Jenkins, T. P., Bjørn, S. P., Nguyen, G. T. T., Lomonte, B., et al. (2025) · mAbs · doi:10.1080/19420862.2025.2553624 · Cited by 3
Anti-B-cell therapy in patients with neuromyelitis optica spectrum disorders
Kotov, S. V., Novikova, E. S., & Котов, А. С. (2021) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2021-4-18-24 · Cited by 3
Response to treatment in NMOSD: the Australasian experience
Clarke, L., Bukhari, W., O’Gorman, C., Khalilidehkordi, E., Arnett, S., Woodhall, M. R., Prain, K. M., Parratt, J. D. E., Barnett, M. H., Marriott, M. P., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103408 · Cited by 3
Current view on the diagnosis and treatment of neuromyelitis optica spectrum disorders exacerbations
Сергеевич, К. В., Прахова, Л. Н., & Totolyan, N. A. (2022) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2022-5-69-76 · Cited by 3
Pestchanker, C., Diaconchuk, M., López, P., Montaño, M. R., Romero, W., Zalazar, G., & Contentti, E. C. (2022) · Multiple Sclerosis Journal · doi:10.1177/13524585221137231 · Cited by 3
Neuromyelitis optic spectrum disorders (NMOSD): from pathogenesis to targeted therapy
Zaitseva, P. A., & Boyko, A. N. (2023) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2023-1s-49-57 · Cited by 5
Antibodies to neural cell surface and synaptic proteins in paraneoplastic neurologic syndromes
Budhram, A., & Sechi, E. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-12-823912-4.00006-2 · Cited by 3
Kamijo, Y., Usuda, M., Matsuno, A., Katoh, N., Morita, Y., Tamaru, F., Kasamatsu, H., & Sekijima, Y. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3593-24 · Cited by 3
“…to be the major pathological mechanism of the disease (2, 3), several biological products, such as complement inhibitors (4), interleukin-6 receptor inhibitors (5, 6), anti-CD19 antibodies (7), and anti-CD20 antibodies (8), are now available in Japan as well as globally to reduce disease activity.”
Autoantibody-mediated central nervous system channelopathies
Binks, S. N. M., & Irani, S. R. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90820-7.00005-7 · Cited by 3
Therapie antikörpervermittelter Enzephalomyelitiden
Ayzenberg, I., & Kleiter, I. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01090-4 · Cited by 3
Inflammatory Demyelinating Diseases of the Central Nervous System
Li, M., & Liu, Q. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-69188-1_8 · Cited by 3
Sun, C., & Liu, Z. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1514687 · Cited by 2
Сергеевич, К. В., Vlasov, Y. V., Evdoshenko, E. P., Korobko, D. S., Matson, M. D., Nilov, A. I., Sokolova, A. A., Totolyan, N. A., Хачанова, Н. В., Shumilina, M. V., et al. (2024) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2024-6-134-143 · Cited by 2
Giannuzzi, F., Carlà, M. M., Crincoli, E., Gambini, G., Hu, L., Boselli, F., Cuffaro, G., Parrilla, C., Rigante, M., Pagliara, M. M., et al. (2025) · International Ophthalmology · doi:10.1007/s10792-025-03535-0 · Cited by 2
“It does this by attaching to and obstructing both the membrane-bound and soluble IL-6 receptors [58, 59].”
Loh, K. M., Cheok, Y. Y., Tang, T. F., Looi, C. Y., Wong, W. F., & Abdullah, S. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf068 · Cited by 2
Li, X., Xue, B., Li, J., Xie, D., Pan, J., Zhu, L.-B., Tong, Q., Lin, J., Zhang, X., Xia, J., et al. (2025) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70128 · Cited by 2
“With a deeper understanding of the disease mechanisms, biologics targeting CD20 [11, 12], interleukin-6 (IL-6) [13, 14], and complement 5 (C5) [15] have demonstrated superior efficacy and are considered high-efficacy therapies.”
Adult T-cell Leukemia Following Satralizumab Treatment for Neuromyelitis Optica Spectrum Disorder
Sakurai, K., Ashikawa, Y., Imaoka, Y., Ohshima, K., Sano, F., Arai, A., Yagishita, N., Araya, N., Nakashima, M., Horibe, E., et al. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5938-25 · Cited by 2
Ikeguchi, R., Shimizu, Y., Kuroda, R., & Todo, K. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106706 · Cited by 2
Fadda, G., & Palace, J. A. (2025) · Multiple Sclerosis Journal · doi:10.1177/13524585251367343 · Cited by 3
“101 This is supported by the positive results from the clinical trials of the IL-6R inhibitor satralizumab in AQP4-NMOSD but not in AQP4-IgG negative NMOSD, 7,8 as well as reports of the effectiveness of tocilizumab in MOGAD leading to the ongoing MOGAD Satralizumab clinical trial.”
Zheng, Y., Hou, J., Jiang, Y., Yu, J., Zhang, N., & Ye, X.-W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1682211 · Cited by 2
Apóstolos‐Pereira, S. L., Damasceno, A., Piccolo, A. C., Mendes, M. F., Ferreira, M. L. B., Alvarenga, R. M. P., da Costa, B. K., Sato, D. K., Brum, D. G., de Melo, E. M. V., et al. (2025) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0045-1812471 · Cited by 2
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
Lin, L., Lin, H., & Lin, S. (2025) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70246 · Cited by 2
CAR-T cells in the treatment of neurological autoimmune diseases
Vonberg, F. W., Schroeder, B. E., Edwards, A. E., Sun, B., Keh, R. Y. S., Ashraghi, M. R., Joe, D. K., Gorgoraptis, N., Rees, J. H., Davies, N. W. S., et al. (2026) · Practical Neurology · doi:10.1136/pn-2025-004890 · Cited by 2
Intravenous immunoglobulin use in neurology
Keller, C. W., Dalakas, M. C., & Lünemann, J. D. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90887-0.00006-7 · Cited by 2
CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy
Wen, M., Zheng, R., Zhang, H., Goldberg, S. Y., Jian, Z., Gao, Y., Cheng, R., Wen, L., Zhao, Y. Y., Kenderian, S. S., et al. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03662-6 · Cited by 2
“In this context, it is important to acknowledge the considerably more mature clinical development of several monoclonal antibody therapies that have already achieved regulatory approval and demonstrated robust efficacy in NMOSD [11, 84–86].”
Zhang, X., Xiong, X., Wei, J., Yan, Y., & Huang, T. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13764-7 · Cited by 2
Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSS
Zadeh, E. S., Vyas, M. V., Sharma, S., Vas, N., Carruthers, R., Chertcoff, A. S., Casserly, C. S., Freedman, M. S., Lee, L., Marrie, R. A., et al. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.107223 · Cited by 2
Frequently Asked Questions on Autoimmune Encephalitis and Related Disorders
Dalmau, J. O., & Graus, F. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108696722.026 · Cited by 3
Multiple sclerosis and neuromyelitis optica spectrum disorders
Ionescu, R.-B., Willis, C. M., Nicaise, A. M., Krzak, G., Hamel, R., Peruzzotti‐Jametti, L., & Pluchino, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00051-4 · Cited by 2
Neurologic autoimmune diseases
Rodríguez, Y., Restrepo, L., Chang, C. C.-C., & Anaya, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95061-9.00033-3 · Cited by 2
Masuda, H., Mori, M., Uzawa, A., Uchida, T., Muto, M., Ohtani, R., Aoki, R., & Kuwabara, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-30594-z · Cited by 2
Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report
Lehrieder, D., Zapantis, N., Pham, M., Schuhmann, M. K., & Haarmann, A. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1297341 · Cited by 2
Chen, Y., Hou, S., Tai, R.-Y., Yu, W.-Y., & Lin, S. (2024) · Neuroimmunology Reports · doi:10.1016/j.nerep.2024.100215 · Cited by 2
Lara, N. T., Gómez-Ballesteros, R., Sepúlveda, M., Orvíz, A., Díaz-Sánchez, M., Boyero, S., Aguado-Valcárcel, M., Cobo‐Calvo, Á., López-Laiz, P., Rebollo, P., et al. (2024) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2024.105732 · Cited by 2
Belova, A. N., Sheiko, G. Е., Ruina, E. A., Makarova, A. E., Александровна, Д. Е., Kukushkina, A. D., Ponevezhskaya, E. V. P., Lysogorskaia, E., & Boyko, A. N. (2024) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202412407216 · Cited by 2
Noll, G., de Lima, M. M., Mantovani, G. P., Gutierrez-Pineda, F., Silva, Y. P., Marcarini, P. G., Reis, L. G. M. R., Konzen, V. R., & Finkelsztejn, A. (2024) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2024.106156 · Cited by 2
Sun, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1499045 · Cited by 2
The role of IL-6 blockers in myasthenia gravis
Waheed, W., & Tandan, R. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00528-3 · Cited by 2
A roadmap to increasing access to AQP4-Ig testing for NMOSD: expert recommendations
Araujo, R. V., Apóstolos‐Pereira, S. L., Jansen, A. M., Lana–Peixoto, M. A., Neto, A. P. G., Rico-Restrepo, M., Alves‐Leon, S. V., & Sato, D. K. (2025) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0045-1801845 · Cited by 2
Current treatment and management of neuromyelitis optica spectrum disorder: areas for improvement
Jahani, S., Rezaeimanesh, N., Owji, M., Bafrani, M. A., Lapevandani, M. M., & Moghadasi, A. N. (2025) · Expert Review of Ophthalmology · doi:10.1080/17469899.2025.2489737 · Cited by 2
“Professor Traboulsee et al. [30] assessed the efficacy and how safe this treatment is.”
Li, D., Ye, J., Hong, Z., & Xiao, H. (2025) · Medicine · doi:10.1097/md.0000000000042067 · Cited by 2
“Both clinical and nonclinical trials [10] have shown that anti-IL-6 therapies can be used for the treatment of neuropathic pain.”
InfluentialVery-late-onset neuromyelitis optica spectrum disorder: a case report and review
Liu, R., Guo, Y.-K., Du, X., & Li, H. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1559872 · Cited by 2
Autoimmune neuro-ophthalmic disorders: pathophysiologic mechanisms and targeted biologic therapies
Rowe, L. W., Barry, Z. R., Mackay, D. D., Lai, K. E., & Ciulla, T. A. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2491603 · Cited by 2
“Satralizumab monotherapy achieved a 30% PDR rate compared to 50% in the placebo group ( p = 0.02 ) [72], while satralizumab added to stable immunosuppressant treatment revealed a PDR of 20% compared to 43% in the placebo group [73].”
InfluentialMiyake, S., Katsura, Y., Baba, M., Tomizawa-Shinohara, H., Matsumoto, Y., & Serizawa, K. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578644 · Cited by 2
“In the clinical trials SAkuraSky and SAkuraStar, it was shown that satralizu-mab significantly reduced the risk of NMOSD relapse compared with placebo in AQP4-IgG + patients (Yamamura et al., 2019; Traboulsee et al., 2020).”
Double-negative NMOSD: from case report to a proposed diagnostic and therapeutic algorithm
Romano, G., Lus, G., Cirillo, M., Coppola, C., Bonavita, S., & Signoriello, E. (2025) · BMC Neurology · doi:10.1186/s12883-025-04326-x · Cited by 2
Randomized Controlled Trials for Neuromyelitis Optica Spectrum Disorder
Cabal-Herrera, A. M., & Mateen, F. J. (2021) · The Neurologist · doi:10.1097/nrl.0000000000000376 · Cited by 2
Ohashi, T. (2022) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12718 · Cited by 2
A Quality Assessment of Aquaporin-4 & Myelin Oligodendrocyte Glycoprotein Antibody Testing
Krett, J. D., Fritzler, M. J., Alikhani, K., & Burton, J. (2022) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2022.324 · Cited by 2
Wang, R., Sun, D., Du, Q., Shi, Z., Chen, H., & Zhou, H. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11776-1 · Cited by 2
“Positive results from two pivotal phase III trials indicated that satralizumab administration could significantly decrease the annualized relapse rate [10, 11].”
BackgroundSharma, K., Seachrist, E., Tolaymat, S., Joseph, J. T., Feizi, P., & Sriwastava, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95343-6.00009-1 · Cited by 2
Abdel-Wahed, L., & Cho, T. A. (2021) · Seminars in Neurology · doi:10.1055/s-0041-1725152 · Cited by 2
Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder
Kim, S. (2022) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2022.1.2 · Cited by 2
“가 변수인 피로 및 통증, 치료 전후 EDSS 점수의 변화는 사트랄리 주맙 치료군과 대조군의 차이는 없었다.(59) 사트랄리주맙의 심한 부 작용은 대조군과 빈도의 차이가 없었으며, 사트랄리주맙 치료를 받은 환자 한 명이 심한 폐렴으로 약을 중단하였다.”
Boyko, A. N. (2023) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2023-1-119-122 · Cited by 2
Nakamagoe, K., Tanaka, M., & Igari, K. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06754-4 · Cited by 1
“A large-scale study examined the effects of satralizumab monotherapy without steroid administration on the prevention of NMOSD relapse [3].”
BackgroundChimeric AQP4-based immunosorbent for highly-specific removal of AQP4-IgG from blood
Wang, X., Ji, F., & Jia, L. (2024) · Journal of Chromatography A · doi:10.1016/j.chroma.2024.464701 · Cited by 1
Qiu, Y., Shen, T., Qiu, W., & Yang, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35142 · Cited by 1
“Satralizumab has been shown to be safe and efficacious in preventing relapses, whether used as monotherapy or in combination with baseline immunosuppressants [9,11].”
BackgroundGeneral Principles of Immunotherapy in Neurological Diseases
Rommer, P. S., Hecker, M., Zrzavy, T., & Zettl, U. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-60006-7_12 · Cited by 1
Poonja, S., Rattanathamsakul, N., & Chen, J. J. (2024) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001335 · Cited by 1
Rehabilitation therapy for aquaporin-4 antibody positive neuromyelitis optica spectrum disorders
Ikeda, J., Muguruma, K., Ochi, K., Kushitani, S., Kaseda, Y., & Maruyama, H. (2024) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.cn-001993 · Cited by 1
Cacciaguerra, L., Storelli, L., Pagani, E., Preziosa, P., Mesaroš, Š., Martinelli, V., Moiola, L., Radaelli, M., Ivanović, J., Tamaš, O., et al. (2024) · Multiple Sclerosis Journal · doi:10.1177/13524585241307154 · Cited by 1
Qi, Y., Liu, R., Zhao, Y., Zhang, L., Zhang, Q., Li, L., Yang, C., Li, Y., & Jiang, W. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08046-5 · Cited by 1
Paladugu, P., Kumar, R., Sporn, K., Ong, J., Song, A., Sekhar, T. C., Gowda, C., Davidoff, N., Shin, S. D., & Lee, A. G. (2025) · Life Sciences in Space Research · doi:10.1016/j.lssr.2025.05.006 · Cited by 3
Nishino, S., Tamura, R., Yoshimura, M., & Ohji, M. (2025) · BMJ Case Reports · doi:10.1136/bcr-2025-266170 · Cited by 1
“13 14 Additionally, it has been reported that IL-6 production levels in the cere - brospinal fluid of patients with MOGAD are comparable with those in AQP4- Ab-positive NMOSD.”
Matsuo, J., Nakahara, K., Hara, Y., & Ueda, M. (2025) · Cureus · doi:10.7759/cureus.86335 · Cited by 1
“However, it did not show a statistically significant effect on pain or fatigue as secondary endpoints, possibly because of limited statistical power and prioritization of secondary endpoints [4,5].”
de Almeida, A. M., Lemus, J. D. L., Cavalcanti, M. E., de Moraes, F. C. A., Filho, F. W., Lopes, P. R. M., Andrade, Í. B., Dantas, C. R., Reis, M. R., & Reyes-Mantilla, M. I. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106705 · Cited by 1
Neuromyelitis Optica Spectrum Disorder: Clinical Features and Treatments Revisited
Watanabe, M. (2025) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.70029 · Cited by 1
Sun, L., Feng, L., Zhang, Y., Shan, M., Tong, C., Zhang, K., Zheng, J., & Fu, X. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111564 · Cited by 1
Matsuyoshi, A., Shinoda, K., Takeuchi, H., Mizutani, K., Kira, Y., Iwao, K., Watanabe, M., Masaki, K., & Isobe, N. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578799 · Cited by 1
Abboud, H., Steingo, B., Vargas, D. L., Patel, J. Y., Willis, M. A., Mao‐Draayer, Y., Khaitov, D., Avila-Ornelas, J., Subei, A. M., Reed, C., et al. (2025) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173251386895 · Cited by 1
Piquet, A., Lowe, M., & Bennett, J. L. (2025) · Neuroimmunology Reports · doi:10.1016/j.nerep.2025.100271 · Cited by 1
Self-citationAbbatemarco, J., Kielhorn, A., Yu, J. C., Fam, S., Myers, K., Poulos, C. M., & Conway, D. S. (2026) · Patient · doi:10.1007/s40271-025-00797-9 · Cited by 1
Hemmer, B. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90887-0.00016-x · Cited by 1
Zhang, L., Yan, R., & Xu, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1647306 · Cited by 2
Fujihara, K., Isobe, N., Miyamoto, K., Niino, M., Nakahara, J., Hattori, S., Tanaka, M., Tahara, M., Suzumura, A., Sakurai, K., et al. (2026) · Multiple Sclerosis Journal · doi:10.1177/13524585261418536 · Cited by 1
“Based on the observation that the relapse rate was numerically lower in SAkuraSky 6 (added to stable immunosuppressant treatment) than in SAkuraStar, 7 and considering the clinical need to prevent relapses until the full therapeutic effect of satralizumab effect is achieved, we believe that the…”
InfluentialACR Appropriateness Criteria® Demyelinating Diseases
Kalnins, A., Lewis, L. M., Soderlund, K. A., Austin, M. J., Chu, S., Hawley, D. B., Kontzialis, M. S., Levy, M., McMenamy, J., Ritter, J., et al. (2026) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2026.02.003 · Cited by 1
Case Report: Rare co-occurrence of NMOSD and capillary leak syndrome treated with satralizumab
Chen, J., Zhang, G., Weng, Q., 林志坚, Shi, X., & Hu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1684380 · Cited by 1
Neuromyelitis Optica Spectrum Disorder
Mariotto, S., & Marignier, R. (2026) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/cont.0000000000001682 · Cited by 1
Neuroglial markers of damage in autoimmune neurology
Dinoto, A., & Mariotto, S. (2026) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864261433329 · Cited by 1
Biologic therapy and brain atrophy in neuromyelitis optica: a Japanese–German longitudinal MRI study
Masuda, H., Anderhalten, L., Mori, M., Shiohama, T., Maikusa, N., Hirano, S., Uzawa, A., Muto, M., Ohtani, R., Uchida, T., et al. (2026) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2025-338166 · Cited by 1
Leypoldt, F., Scheffold, A., & Saggau, C. (2026) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001492 · Cited by 1
Zammar, K., Safan, A. S., Abushalbak, D. J., Daromar, A., Canibaño, B., AlHabil, Y., AbuAlrob, M. A., & Hamid, S. (2026) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2026.578945 · Cited by 1
Rau, M., Claaß, L. V., Steinmann, L. A., Herpertz, J., Richter, M., Leenings, R., Goltermann, J., Meinert, S., Melzer, N., Meuth, S., et al. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106792 · Cited by 1
Wu, L., Wei, M., Gao, F., Zhang, H., Wang, J., Xiang, F., Gao, S., Liu, R., Yin, J., Guo, Y., et al. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-00960-w · Cited by 1
“The ARR was also significantly reduced to 0.166, below the historical immunosuppressant or placebo outcomes (0.32–1.01) [28, 30–33].”
InfluentialAkkawi, N., Mohamed, E. H., & Shatila, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1827687 · Cited by 1
Giglhuber, K., Bertrand, A., Zappe, C., Kleiter, I., Ayzenberg, I., Berthele, A., & the Neuromyelitis Optica Study Group (NEMOS)§ (2026) · Neurological Research and Practice · doi:10.1186/s42466-026-00503-6 · Cited by 1
Wu, L., 顾亮亮, Fan, W., Wei, M., Dai, T., Li, X., Xiao, L., Li, B., Tian, D., Duan, R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04583-4 · Cited by 1
“The full criteria, which align with established precedent from the SAkuraStar and SAkuraSky trials 10,11 and address the recognized limitations of exclusive reliance on EDSS-based assessment, are provided in the study protocol.”
Refining therapeutic targeting of interleukin-6 by signalling mode selectivity
Rose‐John, S., Waetzig, G. H., & Schreiber, S. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01536-x · Cited by 1
Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision‐Making
Hartung, H. (2021) · Annals of Neurology · doi:10.1002/ana.26087 · Cited by 1
“targeting CD19-positive B cells including precursors and plasmablasts,(3) blocking terminal complement activation,(4) or disrupting interleukin-6 signaling pathways.(5,6) All”
Warwick, A. M., Gospe, S. M., & Chen, J. J.-W. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.08.001 · Cited by 1
Application of IL-6 antagonists in autoimmune disorders
Borges, T., Barbosa, A., & Silva, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824390-9.00002-5 · Cited by 1
Possibilities of therapy for neuromyelitis optica spectrum disorders
Novikova, E. S. (2022) · Russian Journal of Child Neurology · doi:10.17650/2073-8803-2021-16-4-49-58 · Cited by 1
Olamkicept(sgp130Fc): The missing trial in Neuromyelitis Optica Spectrum Disorder
Magro, G. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109072 · Cited by 1
Cutler, C. B., Azab, M. A., Lucke-Wold, B. P., Khan, M., Henson, J. C., Gill, A. S., Alt, J. A., & Karsy, M. J. (2023) · World Neurosurgery · doi:10.1016/j.wneu.2022.12.108 · Cited by 1
Richter, D., Bartig, D., Tönges, L., Kümpfel, T., Schwake, C., Gold, R., Krogias, C., & Ayzenberg, I. (2023) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173231184433 · Cited by 1
Sakurai, K., Isahaya, K., Imai, T., & Yamano, Y. (2023) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12760 · Cited by 1
Menezes, R. C., Oliveira, J. D. P., Neto, E. B. C., do Carmo, R. A., Menezes, M. H., Santana, A. P., & de Pontes, M. E. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n1-062 · Cited by 1
The Ruling of Novel Drugs to the Molecular Targets on Variant Pathological
Setiyaningsih, H., Hidayat, I. W., Syarifuddin, A., Santoso, S. B., & Wijayatri, R. (2024) · Advances in Social Science, Education and Humanities Research/Advances in social science, education and humanities research · doi:10.2991/978-2-38476-273-6_2 · Cited by 1
General Principles of Immunotherapy in Neurological Diseases
Rommer, P. S., Hecker, M., Zrzavy, T., & Zettl, U. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-24297-7_12-1 · Cited by 2
Metadata
- Authors
- Traboulsee, A., Greenberg, B. M., Bennett, J. L., Szczechowski, L., Fox, E., Shkrobot, S., Yamamura, T., Terada, Y., Kawata, Y., Wright, P., Gianella-Borradori, A., Garren, H., & Weinshenker, B. G.
- Affiliations
- University of British Columbia (CA)
- The University of Texas Southwestern Medical Center (US)
- University of Colorado Anschutz (US)
- Medical University of Silesia (PL)
- Central Texas Neurology Consultants (US)
- National Center of Neurology and Psychiatry (JP)
- Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
- Genentech (US)
- Mayo Clinic (US)
- Corresponding author
- Traboulsee, Anthony
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 19
- Issue
- 5
- Pages
- 402-412
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC7935419
- OpenAlex
- W3018886418
- Cited by
- 513
- References
- 28
- Citations by year
- 2026: 79 · 2025: 86 · 2024: 75 · 2023: 68 · 2022: 91 · 2021: 80 · 2020: 32
- FWCI
- 44.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 356 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Neurology (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Bayer
- Mitsubishi Tanabe Pharma Corporation
- Teva Pharmaceutical Industries
- Genentech
- Guthy-Jackson Charitable Foundation
- Novartis
- Chugai Pharmaceutical
- Roche
- Japan Blood Products Organization
- National Multiple Sclerosis Society
- MedImmune
- Patient-Centered Outcomes Research Institute
- National Institutes of Health
- Biogen
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- satralizumab, neuromyelitis optica spectrum disorder, IL-6 receptor, monotherapy, relapse prevention, aquaporin-4 antibodies, seronegative NMOSD, Expanded Disability Status Scale, safety, efficacy, monoclonal antibodies, open-label extension, relapse rate, disability progression, treatment discontinuation, adverse events, immunosuppressants
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Neuromyelitis Optica, Treatment Outcome, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
